Polymyositis Market Expected to Gain Momentum Through 2036

DelveInsight's Polymyositis Market Insights, Epidemiology, and Market Forecast 2036 report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology, as well as Polymyositis market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Get a detailed understanding of the evolving Polymyositis treatment landscape: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Facts of the Polymyositis Market Report
• The Polymyositis market size was ~USD 120 million across the 7MM in 2025, and is anticipated to grow at a CAGR of ~20% between 2026 and 2036, driven by improved disease recognition, earlier diagnosis, and increasing adoption of targeted biologic therapies.
• The Polymyositis companies developing therapies in the treatment landscape include AstraZeneca (in partnership with BMS), Pfizer, Argenx, and others.
• In May 2025, Teva Pharmaceuticals, in collaboration with Alvotech, has received FDA approval for SELARSIDTM, a biosimilar to Stelara®. This approval enhances their portfolio in immunomodulatory therapies applicable to polymyositis treatment approaches.
• In January 2025, RESTEM announced that the FDA has granted Fast Track designation for its Restem-L program, which utilizes umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the program's recent Orphan Drug Designation for IIM.
• Anifrolumab (SAPHNELO) is being evaluated in the Phase III JASMINE trial, with AstraZeneca anticipating data in 2027.
• Dazukibart (PF-06823859) from Pfizer has received Orphan Drug Designation and Fast Track Designation from the US FDA, along with PRIME Designation from the EMA.
• Efgartigimod (Argenx) is in Phase III development, with a data readout anticipated in Q3 2026 per the company's May 2026 corporate presentation.
• Positive Phase III outcomes could establish the first disease-specific biologics for Polymyositis, significantly reshaping the competitive landscape and treatment algorithm.

Request a sample PDF to explore comprehensive Polymyositis market forecasts: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Polymyositis Overview
Polymyositis is a rare, chronic autoimmune inflammatory muscle disease characterized by progressive, symmetrical weakness of the proximal skeletal muscles, particularly affecting the shoulders, hips, neck, and thighs. It results from immune-mediated muscle fiber injury, primarily driven by T-cell-mediated inflammation, and is classified among the Idiopathic Inflammatory Myopathies (IIMs). The disease may present alongside extra-muscular manifestations such as interstitial lung disease, dysphagia, and cardiac involvement.
Polymyositis mimics many other myopathies and is considered a diagnosis of exclusion. It most commonly affects adults between ages 50 and 70, and is roughly twice as common in women as in men approximately 75% of US cases in 2025 belonged to female patients. The disease is rare in childhood and typically presents after the second decade of life.
Diagnosis relies on a combination of clinical assessment, elevated serum muscle enzymes, myositis-specific autoantibody testing, MRI, electromyography, and muscle biopsy the diagnostic gold standard, which typically reveals CD8-positive T-lymphocyte infiltration of non-necrotic muscle fibers. The 2017 EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies are widely used to support diagnosis.

Explore how emerging targeted biologics are transforming the future of the Polymyositis market: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Polymyositis Therapies and Key Companies
Key Polymyositis Companies Include:
• AstraZeneca
• Pfizer
• Argenx
• Others

Discover detailed company profiles, pipeline strategies, licensing activities, and competitive benchmarking in DelveInsight's Polymyositis Market Report: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Polymyositis Marketed Therapies
No therapies are currently approved specifically to treat Polymyositis. Existing management focuses on symptom control and immune suppression:
• Corticosteroids - High-dose corticosteroids remain the cornerstone of first-line therapy.
• Steroid-Sparing Immunosuppressants - Methotrexate, azathioprine, mycophenolate mofetil, and tacrolimus are used for long-term disease control.
• IVIG and Rituximab - Reserved for refractory or severe cases.
• Supportive Care - Physical rehabilitation, occupational therapy, nutritional support, and monitoring for complications such as interstitial lung disease and cardiac involvement.

Polymyositis Emerging Therapies

Anifrolumab (SAPHNELO) AstraZeneca / BMS
A fully human monoclonal antibody that blocks the type I interferon receptor subunit 1 (IFNAR1), inhibiting interferon-driven autoimmune inflammation. It holds Orphan Drug Designation from the FDA and is in Phase III (JASMINE) as an add-on to standard of care, with data anticipated in 2027.

Dazukibart (PF-06823859) - Pfizer
A first-in-class humanized monoclonal antibody that selectively neutralizes interferon-beta (IFN-β), a key cytokine implicated in IIM inflammation. It is in a Phase III, multicenter, randomized, placebo-controlled trial, and holds Orphan Drug and Fast Track Designations (FDA) plus PRIME Designation (EMA).

Efgartigimod - Argenx
An FcRn antagonist that accelerates degradation of pathogenic IgG autoantibodies. It is in Phase III development for Polymyositis, with a data readout anticipated in Q3 2026.

Polymyositis Market Drivers
• Advancements in targeted biologic therapies addressing key immune pathways.
• Rising diagnosis and improved disease recognition through better diagnostic tools (myositis-specific antibody testing, muscle MRI, electromyography).
• Favorable regulatory support, including orphan drug incentives and expedited pathways.
• Growing clinical pipeline of precision immunotherapies moving through Phase III trials.
• Potential to reduce reliance on long-term corticosteroids through mechanism-based treatment.

Polymyositis Market Barriers
• No approved disease-specific therapies currently available.
• Continued dependence on corticosteroids and broad immunosuppression.
• Rarity of the disease limits large-scale clinical trial evidence.
• Complex management of extra-muscular manifestations such as interstitial lung disease.
• Diagnosis remains one of exclusion, with variability across healthcare systems.

Request a sample PDF and evaluate Polymyositis market insights: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Polymyositis Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM (United States, EU4 Germany, France, Italy, and Spain, the United Kingdom, and Japan)
• Key Polymyositis Companies: AstraZeneca, Pfizer, Argenx, and others
• Therapeutic Assessment: Current standard-of-care immunosuppressive therapies and emerging Phase III pipeline biologics
• Market Dynamics: Market drivers, barriers, opportunities, and future trends
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Market Entry Strategies, KOL Views, Analyst Views, and Reimbursement Analysis
• Additional Coverage: Epidemiology, Patient Population, Drug Uptake, Clinical Trials, Market Access, and Unmet Needs

Discover the latest Polymyositis Market Opportunity: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
City: Albany State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consulting and Market Research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, competitive intelligence, epidemiology forecasting, pipeline assessment, pricing and reimbursement analysis, and healthcare consulting services that help pharmaceutical, biotechnology, and medical device companies accelerate strategic decision-making and commercial success.

This release was published on openPR.